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Abstract The products of the human ARG gene and the human
ABL gene characterize the Abelson family of non-receptor ty-
rosine protein kinases. Both genes are ubiquitously expressed.
The interactions of these two similar protein kinases are still not
well known, although it has been suggested that they could
cooperate, with redundant actions, to provide intracellular sig-
nals in the cells. Lymphopenia occurs in mice with homozygous
disruption of c-abl, indicating that in certain tissues Arg is un-
able to substitute c-abl functions. In B and T lymphoid cell lines
at di¡erent stages of di¡erentiation, we studied, by a reverse
transcriptase-competitive polymerase chain reaction and West-
ern blotting, Arg and c-abl in order to evaluate whether the
expression pattern of the two genes could give insight as to
why they do not exhibit overlapping roles in lymphocytes and
whether the product levels of the two genes are related to lym-
phoid di¡erentiation. The data showed that their expression is
di¡erently modi¢ed in lymphoid B cell lines. The highest Arg
transcript and protein levels are in the mature B cells. ' 2002
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The products of the human and mouse ARG and ABL
genes and the Drosophila and nematode ABL genes character-
ize the Abelson family of non-receptor tyrosine protein kinase
(TPK) [1^3]. The human Arg and c-abl proteins [3] have a
high degree of amino acid sequence identity (90^94%) in the
tyrosine kinase, SH2 and SH3 domains [3], and have two
isoforms named IA and IB [3^6]. The long C-terminal domain
of Arg is fairly divergent from that of c-abl although both
contain three proline-rich sequences that bind to the SH3
domains of adaptor proteins [7,8]. Furthermore, the actin-
binding sequences present in c-abl are partially conserved in
the C-terminal domain of Arg [9] in which a further F-actin-
binding domain is present [10]. The Arg product is located in
the cytoplasm [5], instead c-abl has a nuclear and cytoplasmic
localization [11]. Arg and c-abl are ubiquitously expressed and
Arg has a higher expression in nervous tissues [12]. Arg
mRNA increases during granulocytic and macrophage-like
di¡erentiation of HL-60 cells [13]. The involvement of Arg
in human pathology has been reported in acute leukemia
[14,15] and in colon cancer [16]. It has been suggested that
these two non-receptor TPKs in the cells in which they are
coexpressed could cooperate with redundant actions that are
still not well known. Both genes could cooperate in DNA
repair or in cell cycle progression mechanisms [1,17], further-
more, interacting with actin ¢laments they play a role in neu-
rulation [18], at the leading edge of growing axons [19] and in
cell migration [20]. Like c-abl, Arg seems to have a role in
genotoxic apoptosis, mediated in Arg by phosphorylation of
the apoptotic Siva1 protein [21]. The development of mice
harboring homozygous disruption of c-abl (c-abl3=3) or Arg
[18,22,23] is likely permitted by the redundant actions. In
c-abl3=3 mice only relatively limited pathologies occur, i.e.
lymphopenia [24,25], indicating that in lymphoid tissues Arg
is unable to substitute c-abl functions. In B and T lymphoid
cell lines at di¡erent stages of di¡erentiation, we studied, by a
reverse transcriptase (RT)-competitive polymerase chain reac-
tion (PCR), Arg and c-abl transcripts and by Western blotting
the respective proteins in order to evaluate whether the ex-
pression pattern of the two genes could give insight as to why
they do not exhibit overlapping roles in lymphocytes and
whether the expression of the two genes is related to lymphoid
di¡erentiation. The data showed that the expression of the
two transcripts is di¡erently modi¢ed in lymphoid B cell lines.
The highest Arg transcript and protein levels are in the mature
B cells.
2. Materials and methods
2.1. Cells
Molt-4 (common thymocyte phenotype, T cells), Jurkat (post-thy-
mic phenotype, T cells), Raji (mature B cells) and TOM-1 (Philadel-
phia chromosome positive cells) cells were obtained from the Amer-
ican Type Culture Collection. Nalm-6 (early pre-B cells), and LP-1
(plasmacytoma) were obtained from the German Collection of Micro-
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organism and Cell Cultures. AllPo (early pre-B cells) [26] was a kind
gift from Dr. A. Biondi (Monza, Italy). Cells were cultured with
RPMI 1640 medium supplemented with 10% fetal calf serum. The
growth rate of the cells was assessed by daily count and viability
was determined by trypan blue exclusion. The growing Raji and AllPo
cells were treated with actinomycin D (10 Wg/ml) to study mRNA
stability at various times after drug exposure. Di¡erentiation of
Nalm-6 from early to late pre-B cells was induced by 12-O-tetradeca-
noyl-phorbol-13-acetate (TPA) (1U1037 mol/l), and the modi¢cations
of the cellular surface antigenic phenotype were analyzed with mono-
clonal antibodies 12, 36 and 72 h after induction [27].
2.2. Immunophenotype and cell cycle analysis
The £ow cytometric cell surface immunophenotype (Table 1) was
determined by speci¢c monoclonal antibodies (Becton Dickinson, San
Jose', CA, USA) and the standard direct immuno£uorescence proce-
dure. Biparametric bromodeoxyuridine (BrdUrd)/DNA £ow cytomet-
ric analysis was performed on at least 20 000 exponentially growing
cells by adding 20 WM BrdUrd for 15 min, 24 or 48 h. The cells were
then directly ¢xed in 70% ethanol before BrdUrd immunodetection
[28] by the FacsCalibur instrument (Becton Dickinson). The percent-
age of the cell cycle phase distribution was calculated by the method
of Krishan and Frei [29].
2.3. RNA extraction, cDNA synthesis and PCR
RNA extraction from exponentially growing cells and DNase treat-
ment have been described previously [13]. An aliquot of 8 Wg of DNA-
free RNA was reverse-transcribed in a 40 Wl reaction, and 1 Wl cDNA
was ampli¢ed as described [13].
2.4. Construction of competitor templates
A 391 bp fragment of Arg cDNA ampli¢ed with 12N and 16N
primers was cloned into the pUC19 EcoRI site. The Arg insert was
cut with BglII‡ and ligated to a 72 bp heterologous synthetic DNA
fragment, generated by PCR ampli¢cation of two 46 bp oligonucleo-
tides overlapping for 20 bp. The resultant 3.15 kb plasmid was line-
arized with NdeI‡ and quantitated (Fig. 1).
L-Actin competitor (Fig. 1) was a truncated recombinant cDNA
generated by PCR ampli¢cation of a 206 bp L-actin cDNA fragment,
obtained as previously described [13]. In a 100 Wl PCR reaction mix-
ture containing 25 pmol each of the antisense B13N and the sense
A14N primers, 1.5 mM MgCl2, 200 WM dNTP, and 2.5 U AmpliTaq
(Applera Italia, Monza, Italy), 1 ng of L-actin cDNA fragment was
ampli¢ed with the following program: denaturation at 94‡C/30 s;
annealing at 55‡C/30 s for two cycles, at 60‡C/30 s for three cycles,
at 65‡C/30 s for 35 cycles; elongation at 72‡C/1 min. The antisense
B13N primer is composed of the juxtaposed B and 13N sequences,
Table 1
Phenotype of human B and T lymphoid cell lines
Lines Stage HLA DR CD34 CD10 CD19 CD20 CD22 CD23 CD37 CD38 CyIg Smlg
Nalm-6 Pre-B ++ 3 ++ ++ 3 R R R +++ R 3
AllPo Pre-B ++ 3 3 +++ 3 R 3 3 +++ 3 3
Raji Mature B +++ 3 +++ +++ +++ +++ R ++ +++ R +++
LP-1 Plasma cell R 3 3 3 3 R + 3 ++ + 3
CD1a CD2 CD3 CD4 CD5 CD7 CD8 CD38
Molt-4 Thymic +++ +++ 3 3 +++ +++ +++ +++
Jurkat Post-thymic +++ +++ ++ 3 3 + 3 R
+++, s 75% positive cells ; ++, 50^75%; +, 25^50%; R , 5^25%; 3, 0^5%. CD, cluster of di¡erentiation; CyIg, cytoplasmic Ig; SmIg, surface
Ig.
Fig. 1. A: Scheme of Arg competitor construction. B: L-Actin competitor construction. C: c-abl competitor (a kind gift from N.C.P. Cross,
Royal Postgraduate Medical School, London, UK).
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which in the 206 bp L-actin cDNA are separated by 63 bp, and of a 5P
tail of 6 nt. The sense A14N primer was the 14N sequence plus a 5 nt
tail at its 5P end. The 154 bp competitor obtained was puri¢ed on
agarose gel and quanti¢ed. The 13N and 14N L-actin primers spanned
exons 3^4 and 4^5 [30], ampli¢ed a 143 bp L-actin competitor and do
not amplify genomic DNA.
The c-abl competitor (Fig. 1) provided as a kind gift by N.C.P.
Cross (Royal Postgraduate Medical School, London, UK) has been
described [31]. The Arg competitor, the L-actin competitor and the
c-abl competitor were serially diluted in the range of 109^10 molecules
per 2.5 Wl with steps at every half order of magnitude on a logarithmic
scale, i.e. 109, 3.2U108, 108, etc. The same set of dilutions for each
competitor was used for all the experiments.
Sequence of primers used for generating competitors: B13N: 5P-
AGCAGGGAGGAGCAATGATCTTGATCTTCATGGTGCCGC-
CAGACAGCACT-3P antisense [30]; A14N: 5P-CGAATTTCC-
TTCCTGGGCATGGAGTCCTGT-3P sense [30] ; and for competitive
PCR reactions: 12N: 5P-ATGAATTCCTTTTAGGTGTGTGTACT-
3P sense [3]; 16N: 5P-ATGAATTCCAAAAGCCCAGACGTCA-3P
antisense [3]; 13N: 5P-GAGGAGCAATGATCTTGATCTTCA-3P
antisense [30] ; 14N: 5P-TTCCTTCCTGGGCATGGAGTCCTG-3P
sense [30] ; A2: 5P-TTCAGCGGCCAGTAGCATCTGACTT-3P sense
[31]; CA3: 5P-TGTTGACTGGCGTGATGTAGTTGCTTGG-3P
antisense [31]. The fragment sizes from competitors and transcripts
are reported in Figs. 1 and 3.
2.5. Competitive PCR
A 2.5 Wl cDNA sample (1 Wl for L-actin) plus 2.5 Wl of competitor
dilution were ampli¢ed in a 50 Wl mixture containing 1.5 mM MgCl2,
200 WM dNTP, 0.5 WM of each primer, and 1.5 U of AmpliTaq. The
ampli¢cation program used for Arg and c-abl was 95‡C/30 s, 60‡C/30
s (for c-abl 64‡C/30 s), 72‡C/30 s and 1 s/cycle of autoextention for 30
cycles. For L-actin it was 95‡C/30 s, 55‡C/30 s, 72‡C/1 min for 35
cycles. The quantity of target mRNA present in the sample was de-
¢ned by the regression curve obtained from densitometric analysis of
electrophoresed bands by plotting log (optical density (OD) target
band/OD competitor band) against log competitor molecules added
in PCR reactions [32]. The value at the equivalence point between the
target molecules and the competitor molecules multiplied by the ratio
between the competitor dimension and the target dimension (1.18 for
Arg; 1.37 for c-abl; 0.69 for L-actin) gives the number of target
molecules in the sample, expressed as molecules per Wg of RNA.
The RNA integrity and the variations of RNA or cDNA among
samples were checked using as a reference the L-actin mRNA level
of each cell line, established as a mean of four independent experi-
ments performed in duplicate. The Arg and c-abl transcript levels in
the same sample were normalized by multiplying by the ratio between
the mean level of L-actin of the respective cell line and the L-actin
level of the speci¢c sample.
2.6. Western blotting
Cells were lysed with 1% Triton X-100, 10 mM Tris^HCl pH 7.4,
150 mM NaCl, 20 Wg/ml leupeptin, 5 Wg/ml aprotinin, 1 mM PMSF.
The protein concentration was determined by Bio-Rad microassay
(Hercules, CA, USA). The lysates (100 Wg) separated on a 7.5%
SDS^PAGE gel were blotted to nitrocellulose membrane. The Pon-
ceau S stain of the blot was obtained to show equal loading of lanes.
Western blotting was performed with antibodies speci¢c to mouse Arg
[18] directed against the SH2 and SH3 domains (a kind gift of A.
Koleske, Yale University, CT, USA). These antibodies proved to be
able to recognize, with Western blot, human Arg expressed in bacteria
and were unable to cross-react with human Abl, when tested with a
BCR/ABL positive TOM-1 human cell line. The anti-Abl 8E9 anti-
bodies (Pharmingen, San Diego, CA, USA) and anti-actin antibodies
(Sigma-Aldrich, Saint Louis, MO, USA) were used to detect c-abl and
L-actin proteins respectively. The detection has been performed with
secondary antibodies coupled to horseradish peroxidase and with
SuperSignal Detection System (Pierce, Rockford, IL, USA).
Fig. 2. A: Growth rate of lymphoid cell lines. Exponentially growing cells were plated at a density of 3U105/ml (Nalm-6 cells, 1U106/ml). The
total number of cells determined in a Thoma chamber is expressed as meansRS.E.M. of four separate experiments. Cell mortality during the
exponential growth assessed by trypan blue exclusion was in the range of 5^7%. B: Percentage of the cell cycle phase distribution (E G1 ;
S; F G2/M) during exponential growth (day 2) as determined by biparametric BrdUrd/DNA £ow cytometric analysis (left). Representative £ow
cytometric analysis in Raji cells treated for 15 min with BrdUrd (right).
Fig. 3. Quanti¢cation with competitive PCR of Arg and c-abl tran-
scripts. Representative experiment in the Raji B cell line. The regres-
sion curve obtained by plotting log (OD sample band/OD competi-
tor band) against log competitor molecules gave the equivalence
point between the number of molecules of sample transcript and
competitor. The value multiplied by a factor of 1.18 for Arg and
1.37 for c-abl gave the number of target molecules that will be ex-
pressed as molecules per Wg of RNA.
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3. Results
3.1. Cell line growth rate, cell cycle and phenotype
The growth rate of di¡erent cell lines showed that whereas
Jurkat and Molt-4 cells had substantially the same growth
rate, the cell lines AllPo, Nalm-6 and LP-1 grew more slowly
and Raji cells had the highest growth rate (Fig. 2).
Cell cycle analysis showed that the highest percentage of
Nalm-6, Raji and LP-1 cells was in the S phase, whereas the
remaining cell lines were more represented in the G1 phase.
Fig. 4. A: Level of Arg, c-abl and L-actin transcripts in human B and T lymphoid cell lines as evaluated by competitive RT-PCR. The values,
expressed as number of transcript molecules/Wg total RNA, are meansRS.E.M. of four independent experiments. B: Level of Arg and c-abl
transcript levels in Nalm-6 cells treated with TPA for 12, 36 and 72 h, as evaluated by competitive PCR. Maturation of Nalm-6 from pre-B to
late pre-B phenotype was established on the basis of the variation in surface markers: appearance of CD20, increment in CD22 and CD19, re-
duction of CD10. C: Western blot analyses with anti-Arg, anti-c-abl and anti-L-actin antibodies of 100 Wg cell lysate from B and T cell lines.
D: Level of Arg and c-abl proteins evaluated by densitometric analysis of Western blot. The values, expressed as relative OD, have been re-
ferred to Raji cell values considered equal to 1.
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The percentage of cells in the G2/M phase was low for all cell
lines except Raji cells, in which the value was two-fold (Fig.
2).
The phenotype of the studied cell lines on the basis of sur-
face markers is shown in Table 1 and evidenced the AllPo and
Nalm-6 as pre-B cells, Raji as mature B cells, LP-1 as plasma
cells, Molt-4 as a thymic cell, and Jurkat as a post-thymic cell
[33].
3.2. Level of Arg, c-abl and L-actin transcript in lymphoid
cell lines as evaluated by competitive PCR
The principal condition to derive absolute quantitative in-
formation by competitive PCR is that the target and compet-
itor sequences are ampli¢ed with equal e⁄ciencies denoted by
the regression curves with the slope close to 31, with r=1
(Fig. 3) and the ratio of competitor band/sample band be-
tween 1.5 and 0.5 [32]. The ampli¢ed Arg transcript showed
an almost identical level in the less mature pre-B cells (Nalm-
6, AllPo), in the immature T cell line (Molt-4), and in the
post-thymic cell line (Jurkat), whereas in the Raji cells (ma-
ture B cell) and in the LP-1 cells (plasma cell) it was much
higher (21 and 18U103 molecules/Wg RNA) (Fig. 4). The c-abl
transcript level in the cell lines tested was two to three log
higher than the Arg transcript of the corresponding cell lines
(Fig. 4). In the two T cell lines, the c-abl transcript level was
similar. Instead, in B cell lines the mature (LP-1) and mainly
the immature (Nalm-6) cells showed a high level of c-abl
mRNA, with respect to the other two cell lines, Raji (mature)
and AllPo (immature), that had low levels of c-abl. The ratio
Arg/Abl that can be derived from our data re£ects the pattern
of Arg expression. The six cell lines studied had their own
characteristic level of L-actin mRNA. All the data, obtained
with the same set of competitor dilutions, were checked with
other sets of independent dilutions, and similar results were
obtained.
3.3. Arg and c-abl transcript in the TPA-treated Nalm-6
cell line
Induction of di¡erentiation of Nalm-6 cells from the pre-B
to late pre-B phenotype by TPA, as proven by phenotypic
variation of surface markers [27], showed that the Arg and
c-abl mRNA level did not vary signi¢cantly after 12, 36 and
72 h of treatment (Fig. 4).
3.4. Characterization of Arg mRNA half-life
The Arg transcript half-life was established in Raji and
AllPo cells. The cells were treated with actinomycin D (10
Wg/ml) to obtain the maximal blockage of transcription.
Two independent actinomycin treatment experiments per cell
line were performed, and equivalent amounts of RNA were
extracted from cells taken at various intervals of up to 3 h.
Actinomycin D experiments might give variable values and
transcripts may have di¡erent stabilities in di¡erent cells
[34,35], nevertheless, our experiments gave comparable results
and the estimated half-life of Arg mRNA was w60 min in
Raji and AllPo cells (Fig. 5).
3.5. Level of Arg and c-abl protein in lymphoid cell lines
as evaluated by Western blotting
Western blot analysis of lymphoid cell line lysates shows
with speci¢c anti-c-abl antibodies a discrete band of 145
kDa and with anti-mouse Arg antibodies able to recognize
also human Arg [36] a set of bands as previously shown
[18]. These bands located between the 105 and 160 kDa mo-
lecular weight markers (Fig. 4) have a di¡erent reciprocal
intensity among the cell lines studied. The value of Arg and
c-abl protein level has been obtained by densitometric analysis
normalizing the respective OD with the respective L-actin OD
in each cell line. Considering an equal protein loading of the
lanes, as evidenced by the Ponceau S stain of the Western
blots (data not shown), this procedure provides a reliable
representation of the relative level of proteins. The normalized
Arg and c-abl OD in each cell line has been related to the
respective values of Raji cells considered equal to 1. The cu-
mulative value of the di¡erent protein bands of Arg has been
considered. Following these procedures the Arg protein level
results to be about four to ¢ve-fold higher in Raji and LP-1
cell lines than in less mature B cells and in both T cell lines.
The highest Abl protein level is in Nalm-6 cells. Overall these
patterns of protein expression are in accordance with the Arg
and Abl pattern of the correspondent transcript expression.
4. Discussion
Mice with homozygous inactivation of the c-abl locus dis-
play thymic and splenic atrophy with de¢ciencies of B and T
lymphoid progenitors and a slow maturation of pro-B cells to
pre-B cells [22^25]. Also v-abl and BCR/ABL, the transform-
Fig. 5. E¡ect of actinomycin D on Arg expression in Raji (b) and
AllPo (O) cells. A: Densitometric evaluation of a gel-electropho-
resed Arg-ampli¢ed band plotted on a semilogarithmic scale. Equal
amounts of RNA (8 Wg) extracted from cells at various time points
were reverse-transcribed and the amount corresponding to 0.2 Wg
was ampli¢ed with linear ampli¢cation for 35 cycles as described
[13]. The control sample was de¢ned as 100% amount of Arg
mRNA. The half-life (50% relative OD point) was extrapolated
from the best ¢t line obtained using non-linear regression analysis.
B: Gel electrophoresis of an RNA aliquot corresponding to 2U105
Raji and AllPo cells treated with actinomycin D at various time
points.
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ing variants of c-abl, have a role in B lymphoid tissue [37^39]
that seems to be a sensitive target of c-abl functions. In lym-
phoid tissues the redundant functions of Arg and c-abl
[18,22,23] seem not present since Arg is unable to replace
the c-abl functions [24,25].
Our data showed that there is a di¡erence in the expression
pattern of Arg and c-abl transcripts and proteins in the six
lymphoid cell lines studied. The level of Arg transcript and
proteins increases in the more di¡erentiated B lymphoid cells
(Raji, LP-1). The increment of Arg is not related to cell
growth rate or cell cycle phases as reported [21] and is in
accordance with the observations that endogenous Arg and
c-abl per se do not play a crucial role in normal cell cycle
progression [18,40]. Contrasting results, instead, were ob-
tained when c-abl was overexpressed in cells in which, how-
ever, a cytotoxic e¡ect seems to be prevalent [1,17,41]. It
should be noted that we found the highest level of c-abl
mRNA in the two B cell lines with slowest growth rate
(Nalm-6, LP-1). The level of c-abl transcripts in the six cell
lines was not related to di¡erentiation. Our data showing the
increment of Arg level in the mature B lymphoid cells are in
accordance also with previous observations made in granulo-
cytes, monocytes [13] and neurons [18], and support the hy-
pothesis that high levels of Arg are related to the mature state
of speci¢c cells. The hypothesis is not contradicted by the data
showing no increment of Arg in Nalm-6 cells after TPA treat-
ment. In fact, the di¡erentiation obtained, from early pre-B to
late pre-B stage, is very weak [27] and may not be enough to
determine an increment in Arg mRNA, if this is a phenome-
non elicited in more mature cells.
The actinomycin D experiments suggested that the incre-
ment in Arg mRNA in Raji cells with respect to AllPo cells
was due to transcription activation since the transcript half-
lives are similar. All together, the data suggest that in B cell
maturation, but not in T cells, Arg and c-abl have a di¡erent
behavior concerning the expression. The di¡erent modi¢ca-
tion of expression may suggest that the two genes, in B cells,
are involved in di¡erent pathways with independent functions
without overlapping roles and the invoked redundant actions
[18,22^25] might be lost. The lack of redundancy could be due
to the fact that the poorly expressed Arg, being involved in an
alternative pathway, is not enough to also support the redun-
dant actions. Such a hypothesis is supported by the evidence
that in homozygous c-abl3=3 mice the pro-B and pre-B cells,
with a low level of Arg, su¡er more from the lack of c-abl
than the mature B cells, which have a high level of Arg [22^
25,40]. Future investigations should assess whether the incre-
ment in Arg is related to one of its two speci¢c forms and
evaluate whether the forms IA and IB of Arg have an even-
tual role in apoptosis, keeping into account that an anti-apo-
ptotic role [42] has been assigned to the type IV myristoylated
form of murine c-abl, which is more abundant in mature B
cell lines than type I, which instead is the major form in the
less di¡erentiated pre-B cell lines [43]. In fact, although nu-
clear c-abl can activate the genotoxic apoptosis, it has been
otherwise suggested that during cell adhesion and contact in-
hibition [44,45] there is an increased cytoplasmic localization
of c-abl that is consistent with an attenuation of the apoptosis
response.
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